Free Trial
→ $0. Later: $29.97. (From Profits Run) (Ad)tc pixel
NASDAQ:ALP

Portage Biotech Q2 2026 Earnings Results & Report

Portage Biotech logo
$3.10 -0.14 (-4.32%)
As of 11/12/2026 04:00 PM Eastern

Portage Biotech reported Q2 2026 earnings on January 21, 2026. The company reported EPS of -$206.50.

Research:ProfileEarnings HistoryForecast

Earnings Announcement Details

Quarter
Q2 2026
Report Date
Time
After Market Closes

Portage Biotech EPS Results

Actual EPS
-$206.50
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Portage Biotech Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Conference Call Resources

Portage Biotech Q2 2026 Earnings FAQ

Portage Biotech (NASDAQ:ALP) reported earnings of -$206.50 per share for Q2 2026. The report was announced on Wednesday, January 21, 2026.

Portage Biotech Earnings Headlines

Alpha Compute Joins the Board of the Confidential Computing Consortium; Takes the Stage with Fortanix, NVIDIA and ElevenLabs at NVIDIA GTC Berlin
October 22, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/22/3386190/0/en/alpha-compute-joins-the-board-of-the-confidential-computing-consortium-takes-the-stage-with-fortanix-nvidia-and-elevenlabs-at-nvidia-gtc-berlin.html
Alpha Compute Signs Binding GPU Contract, Leasing ALPHA-03 cluster under Four-Year, $81.7 Million Agreement in its Missouri Superintelligence Factory
October 14, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/14/3380592/0/en/alpha-compute-signs-binding-gpu-contract-leasing-alpha-03-cluster-under-four-year-81-7-million-agreement-in-its-missouri-superintelligence-factory.html
I'm handing you this one free
Elon Musk doesn't own the chip powering every Tesla, every Starlink dish, and every AI satellite he builds. He licenses it from one overlooked company. That supplier just got a major catalyst. Musk filed to launch 1,000,000 satellites, a move analyst Dylan believes could drive a 100X bigger bill for this chipmaker starting December 8th.tc pixel
 |  Behind the Markets (Ad)
Alpha Compute's GAMEE Reports Q3 Record 94% YoY Growth, Reaches Monthly Profitability with over 118 million game-plays, Expands Into AI-Powered Consumer Applications
October 7, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/07/3376286/0/en/alpha-compute-s-gamee-reports-q3-record-94-yoy-growth-reaches-monthly-profitability-with-over-118-million-game-plays-expands-into-ai-powered-consumer-applications.html
Alpha Compute Corp. Signs Agreement with AI Platform to deliver Compute via its ALPHA-02 Cluster in Sweden, with a total value of $71.9 Million
October 6, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/06/3375456/0/en/alpha-compute-corp-signs-agreement-with-ai-platform-to-deliver-compute-via-its-alpha-02-cluster-in-sweden-with-a-total-value-of-71-9-million.html
Alpha Compute Operating Oil and Gas Assets Due Diligence Estimates 2.9 million barrels of Oil Reserves and $100 million in Natural Gas reserves that can power 200MW for Data Center
September 29, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/29/3370820/0/en/alpha-compute-operating-oil-and-gas-assets-due-diligence-estimates-2-9-million-barrels-of-oil-reserves-and-100-million-in-natural-gas-reserves-that-can-power-200mw-for-data-center.html
See More Portage Biotech Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Portage Biotech? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Portage Biotech and other key companies, straight to your email.

About Portage Biotech

Portage Biotech (NASDAQ:ALP) is a clinical-stage biotechnology company focused on developing immuno-oncology treatments for cancer. The company’s approach is designed to stimulate the immune system and promote targeted destruction of tumor cells, with the goal of addressing cancers that may be difficult to treat with conventional therapies.

Portage’s lead investigational product is INT230-6, an intratumoral therapy licensed from Intensity Therapeutics. The treatment is designed to deliver anticancer agents directly into tumors and may also activate an immune response against cancer cells elsewhere in the body. INT230-6 has been evaluated in clinical studies involving patients with advanced solid tumors, including breast cancer and sarcoma.

Portage Biotech was formed through a series of corporate transactions involving biotechnology and investment entities and is incorporated in the British Virgin Islands. Its development activities have involved clinical research and collaborations across North America and other international markets. Ian Walters has served as the company’s chief executive officer and a director. The company’s common shares trade on the Nasdaq Capital Market under the ticker symbol PRTG.

View Portage Biotech Profile
Earnings Tools